{"id":44289,"date":"2025-10-24T22:48:58","date_gmt":"2025-10-24T14:48:58","guid":{"rendered":"https:\/\/flcube.com\/?p=44289"},"modified":"2025-10-24T22:48:58","modified_gmt":"2025-10-24T14:48:58","slug":"hengrui-launches-henagliflozin-triple%e2%80%91combination-metformin-for-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44289","title":{"rendered":"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes"},"content":{"rendered":"\n<p>Hengrui Medicine (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>,\u202f<a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) today announced the commercial launch of its first independently developed oral triple\u2011combination hypoglycemic formulation: <strong>Henagliflozin\/Retagliptin\/Metformin Extended\u2011Release Tablets (I &amp;\u202fII)<\/strong>. The product is approved for adults with type\u202f2 diabetes mellitus (T2DM) whose glycaemic control remains inadequate on metformin hydrochloride alone, when combined with diet and exercise.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile\"><strong>Product Profile<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Class<\/th><th>Key Mechanism<\/th><th>Clinical Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Henagliflozin<\/strong><\/td><td>SGLT2 inhibitor<\/td><td>Inhibits renal SGLT2 \u2192 \u2191 urinary glucose excretion<\/td><td>\u2193 fasting glucose, weight loss<\/td><\/tr><tr><td><strong>Retagliptin<\/strong><\/td><td>DPP\u20114 inhibitor<\/td><td>Blocks DPP\u20114 \u2192 \u2191 GLP\u20111 \u2192 \u2191 insulin, \u2193 glucagon<\/td><td>Post\u2011prandial glucose control<\/td><\/tr><tr><td><strong>Metformin<\/strong><\/td><td>Biguanide<\/td><td>Reduces hepatic gluconeogenesis<\/td><td>Baseline glycaemic control<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011China<\/strong>: Henagliflozin is China\u2019s first independently developed SGLT2i; Retagliptin is the first domestic DPP\u20114i.<\/li>\n\n\n\n<li><strong>Extended\u2011Release<\/strong>: Tablets (I &amp;\u202fII) provide sustained drug release, improving adherence.<\/li>\n\n\n\n<li><strong>Fixed\u2011Dose Combination<\/strong>: One pill replaces multiple tablets, simplifying therapy for patients.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence\"><strong>Clinical Evidence<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fIII Trial (SHR3824\u2011SP2086\u2011MET\u2011301)<\/strong><\/li>\n\n\n\n<li>1,540 participants; 12\u2011week double\u2011blind crossover.<\/li>\n\n\n\n<li><strong>HbA1c reduction<\/strong>: 1.54\u202f% (baseline \u2192 7.00\u202f%).<\/li>\n\n\n\n<li><strong>Responder rate<\/strong>: 57.4\u202f% achieved HbA1c\u202f\u2264\u202f7\u202f%.<\/li>\n\n\n\n<li><strong>Additional benefits<\/strong>: 0.52\u20110.65\u202f% greater HbA1c lowering versus dual\u2011combination; modest weight loss and systolic BP reduction.<\/li>\n\n\n\n<li><strong>Safety<\/strong>: Low hypoglycaemia risk, tolerable GI profile.<\/li>\n\n\n\n<li><strong>Bioequivalence (HR20031\u2011101)<\/strong> &amp; <strong>Food\u2011Effect PK (HR20031\u2011102)<\/strong><\/li>\n\n\n\n<li>Demonstrated comparable absorption across formulations and with or without food.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-market-impact\"><strong>Regulatory &amp; Market Impact<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Approval<\/strong>: Granted by the China Food and Drug Administration (CFDA) under the \u201cClass\u202f1 Chemical Novel Drug\u201d pathway.<\/li>\n\n\n\n<li><strong>Market Position<\/strong>: Addresses a critical unmet need\u2014patients who cannot achieve target HbA1c on metformin monotherapy.<\/li>\n\n\n\n<li><strong>Commercial Strategy<\/strong>: Hengrui will partner with leading hospitals for early\u2011adoption programs and is preparing for reimbursement negotiations with Chinese payers.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h2>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hengrui Medicine (SHA: 600276,\u202fHKG: 1276) today announced the commercial launch of its first independently developed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44290,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,2586,4228,15,852],"class_list":["post-44289","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-product-approvals","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hengrui Medicine (SHA: 600276,\u202fHKG: 1276) today announced the commercial launch of its first independently developed oral triple\u2011combination hypoglycemic formulation: Henagliflozin\/Retagliptin\/Metformin Extended\u2011Release Tablets (I &amp;\u202fII). The product is approved for adults with type\u202f2 diabetes mellitus (T2DM) whose glycaemic control remains inadequate on metformin hydrochloride alone, when combined with diet and exercise.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44289\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes\" \/>\n<meta property=\"og:description\" content=\"Hengrui Medicine (SHA: 600276,\u202fHKG: 1276) today announced the commercial launch of its first independently developed oral triple\u2011combination hypoglycemic formulation: Henagliflozin\/Retagliptin\/Metformin Extended\u2011Release Tablets (I &amp;\u202fII). The product is approved for adults with type\u202f2 diabetes mellitus (T2DM) whose glycaemic control remains inadequate on metformin hydrochloride alone, when combined with diet and exercise.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44289\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-24T14:48:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2402.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44289#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44289\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes\",\"datePublished\":\"2025-10-24T14:48:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44289\"},\"wordCount\":292,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44289#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2402.webp\",\"keywords\":[\"Diabetes\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"Product approvals\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44289#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44289\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44289\",\"name\":\"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44289#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44289#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2402.webp\",\"datePublished\":\"2025-10-24T14:48:58+00:00\",\"description\":\"Hengrui Medicine (SHA: 600276,\u202fHKG: 1276) today announced the commercial launch of its first independently developed oral triple\u2011combination hypoglycemic formulation: Henagliflozin\\\/Retagliptin\\\/Metformin Extended\u2011Release Tablets (I &\u202fII). The product is approved for adults with type\u202f2 diabetes mellitus (T2DM) whose glycaemic control remains inadequate on metformin hydrochloride alone, when combined with diet and exercise.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44289#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44289\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44289#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2402.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2402.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44289#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","description":"Hengrui Medicine (SHA: 600276,\u202fHKG: 1276) today announced the commercial launch of its first independently developed oral triple\u2011combination hypoglycemic formulation: Henagliflozin\/Retagliptin\/Metformin Extended\u2011Release Tablets (I &\u202fII). The product is approved for adults with type\u202f2 diabetes mellitus (T2DM) whose glycaemic control remains inadequate on metformin hydrochloride alone, when combined with diet and exercise.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44289","og_locale":"en_US","og_type":"article","og_title":"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes","og_description":"Hengrui Medicine (SHA: 600276,\u202fHKG: 1276) today announced the commercial launch of its first independently developed oral triple\u2011combination hypoglycemic formulation: Henagliflozin\/Retagliptin\/Metformin Extended\u2011Release Tablets (I &\u202fII). The product is approved for adults with type\u202f2 diabetes mellitus (T2DM) whose glycaemic control remains inadequate on metformin hydrochloride alone, when combined with diet and exercise.","og_url":"https:\/\/flcube.com\/?p=44289","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-24T14:48:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2402.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44289#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44289"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes","datePublished":"2025-10-24T14:48:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44289"},"wordCount":292,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44289#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2402.webp","keywords":["Diabetes","Hengrui Pharmaceuticals","HKG: 1276","Product approvals","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44289#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44289","url":"https:\/\/flcube.com\/?p=44289","name":"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44289#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44289#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2402.webp","datePublished":"2025-10-24T14:48:58+00:00","description":"Hengrui Medicine (SHA: 600276,\u202fHKG: 1276) today announced the commercial launch of its first independently developed oral triple\u2011combination hypoglycemic formulation: Henagliflozin\/Retagliptin\/Metformin Extended\u2011Release Tablets (I &\u202fII). The product is approved for adults with type\u202f2 diabetes mellitus (T2DM) whose glycaemic control remains inadequate on metformin hydrochloride alone, when combined with diet and exercise.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44289#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44289"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44289#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2402.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2402.webp","width":1080,"height":608,"caption":"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44289#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Launches Henagliflozin Triple\u2011Combination Metformin for Type\u202f2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2402.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44289"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44289\/revisions"}],"predecessor-version":[{"id":44291,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44289\/revisions\/44291"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44290"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}